Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.37 |
| ▸ | BHMT | Q93088 | 3/20 | 0.35 |
| ▸ | MVD | P53602 | 1/20 | 0.34 |
| ▸ | TPI1 | P60174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345202 | 0.86 | BHMT (0.33) | BHMT | |
| SCHEMBL6348366 | 0.85 | BHMT (0.37) | LPAR3LPAR2LPAR1BHMT | |
| SCHEMBL21407715 | 0.79 | LPAR3 (0.41) | LPAR3LPAR2LPAR1TPI1 | |
| SCHEMBL6508790 | 0.78 | BHMT (0.35) | LPAR3LPAR2LPAR1BHMT | |
| SCHEMBL9943661 | 0.76 | LPAR3 (0.42) | LPAR3LPAR2LPAR1TPI1 | |
| SCHEMBL11605559 | 0.76 | LPAR3 (0.47) | LPAR3LPAR2LPAR1TPI1 | |
| SCHEMBL13053716 | 0.74 | LPAR3 (0.37) | LPAR3LPAR2LPAR1 | |
| SCHEMBL3046776 | 0.74 | LPAR3 (0.46) | LPAR3LPAR2LPAR1 | |
| SCHEMBL6344059 | 0.74 | GRM4 (0.35) | BHMT | |
| SCHEMBL3286679 | 0.74 | LPAR3 (0.37) | LPAR3LPAR2LPAR1MVDTPI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2005068418-A1 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | LPAR3 1589/4885LPAR2 1633/4885LPAR1 1119/4885 |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | LPAR3 1587/4885LPAR2 1641/4885LPAR1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.